On criticising Israel. Response from author of original paper. Comparison of the number of Palestinians killed by the Israeli Defence Force (IDF) with those killed in 9/11.

D. Summerfield

DOI: https://doi.org/10.1136/bmj.b1076

British Medical Journal

Abstract:

What problem does this paper attempt to address?

Monochromatic light sources in testing image intensifier tubes

K. Chrzanowski,omiej Radzik

Abstract:Military standards and literature sources recommend use of polychromatic light source of 2856K color temperature in testing image intensifier tubes. Tungsten halogen bulbs are standard sources of radiation used in commercially available test stations. However, there are two main disadvantages of tungsten bulbs: short life time and temporal changes of both light power and light spectrum. Application of monochromatic semiconductor sources in testing of image intensifiers as possible alternative of halogen bulbs is analyzed in this paper. It is shown that, if calibrated properly, monochromatic semiconductor sources can be used in stations for testing image intensifier tubes. Military standards require use of polychromatic light sources of 2856K color temperature in testing image intensifier tubes[1.a.i.[1]-1.a.i.[6]]. Tungsten halogen bulbs have been standard sources of radiation used in commercially available test stations for last few decades in testing image intensifier tubes [1.a.i.[7],1.a.i.[8]]. However, tungsten halogen bulbs have several significant limitations. First, they are not stable and emitted flux varies significantly in time. Second, they are characterized by short life time. Third, due to significant temporal inertia it is necessary to use mechanical shutters to enable tests of temporal characteristics of image intensifier tubes (II tubes). Sensitivity of image intensifier tubes depends significantly on wavelength. Therefore, illumination of the photocathode with 2856K color temperature light is not equivalent to illumination with monochromatic light of the same radiation power. However, let us analyze if properly calibrated monochromatic sources can replace 2856K color temperature halogen bulbs in test equipment to be used for testing image intensifier tubes and if accurate measurement of photometric parameters of II tubes is still possible. Quantitative relationships between input illuminance and output luminance is measured during the photometric tests of II tubes. The MIL standards state very precisely the necessary illuminance levels of 2856K color radiation to be used during measurement of photometric parameters of II tubes. The conversion coefficient between the illuminance level of 2856K light and the equivalent illuminance level of monochromatic light depends on spectral sensitivity curve of the tested tube that can vary with different tubes. Therefore we should use different conversion coefficients in order to calibrate properly the monochromatic source used during tests of tubes of different spectral sensitivity. * E-mail: kch@inframet.pl This feature is a significant drawback of semiconductor light sources but still in case of testing large number of II tubes of the same spectral sensitivity such monochromatic sources should be an interesting alternative of typical halogen bulbs. Here we will analyze possible application of monochromatic semiconductor sources (LED diodes) in testing of image intensifier tubes. These monochromatic sources are much more stable, are characterized by negligible temporal inertia and do not cause polychromatic aberration. Such sources are used sometimes in commercially available stations for testing II tubes [1.a.i.[7],1.a.i.[8]]. However, so far their applications have been limited to use in measurements of imaging parameters (resolution, MTF, image quality etc) of II tubes when, according to MIL standards, requirements on accuracy of illumination level are low. Here we are to investigate if it is possible to use semiconductor light sources in testing photometric parameters of II tubes (luminous sensitivity, luminance gain, etc) when requirements on accuracy of illumination level are high. In order to calibrate properly monochromatic source to be used instead of standard polychromatic light sources we will need an instrument that is sensitive to both polychromatic and monochromatic light. Let us make an assumption that we will use typical illuminance meters of spectral characteristics identical as spectral characteristics of humans eye as the sensing instrument of both polychromatic and monochromatic illumination at tube photocathode plane. The illuminace meters of sensitivity over 1 mlx are relatively low cost meters available at photometric laboratories. Next, let as assume that we will use a monochromatic source emitting light in the spectral range where both the tested II tubes and the illuminance meters are sensitive: from about 0.5 μm to 0.65μm. Krzysztof Chrzanowski, *1,2 Tomasz Raźniewski, Bartłomiej Radzik Military University of Technology, 2 Kaliski str., 00-908 Warsaw, Poland, Inframet, Graniczna 24, Kwirynow, 05-082 Stare Babice, Poland Received April 28, 2009; accepted June 29, 2009; published June 30, 2009 http://www.photonics.pl/PLP © 2009 Photonics Society of Poland PHOTONICS LETTERS OF POLAND, VOL. 1 (2), 79-81 (2009) 80 Now, let us analyse a situation when the photocathode of the image intensifier tube was illuminated using polychromatic 2856 K light and the illuminance meter recorded illuminance level Ep, and when the photocathode of the image intensifier tube was illuminated using monochromatic light the illuminance meter recorded illuminance level Em. Let us find what is the relationship between Ep and Em necessary to achieve situation when both light sources generate the same luminance level at the screen of the illuminated II tube. The light coming to the photocathode represent a certain stimulus that is measured by the illuminance meter in photometric units perfectly suitable for humans eye. Here however, let us analyse a case when the receptor of this stimulus is not human eye but image intensifier tube of significantly different spectral curve. If we use a light meter of spectral curve identical as tube curve then the corrected indication of the illuminace meter illuminated using polychromatic light Ep(cor) would be
Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Natalie Arnold,Martin Rehm,Gisela Büchele,Raphael Simon Peter,Rolf Erwin Brenner,Klaus-Peter Günther,Hermann Brenner,Wolfgang Koenig,Dietrich Rothenbacher

DOI: https://doi.org/10.3390/jcm9103107

2020-09-26

Abstract:Background: Subjects with osteoarthritis (OA) are at increased risk for cardiovascular (CV) and all-cause mortality. Whether biomarkers improve outcome prediction in these patients remains to be elucidated. We investigated the association between growth differentiation factor 15 (GDF-15), a novel stress-responsive cytokine, and long-term all-cause mortality among OA patients. Methods: Within the Ulm Osteoarthritis Study, GDF-15 has been measured in the serum of 636 subjects, who underwent hip or knee arthroplasty between 1995 and 1996 (median age 65 years). Results: During a median follow-up of 19.7 years, a total of 402 deaths occurred. GDF-15 was inversely associated with walking distance. Compared to the bottom quartile (Q), subjects within the top quartile of GDF-15 demonstrated a 2.69-fold increased risk of dying (hazard ratio (HR) (95% confidence interval (CI)) 2.69 (1.82-3.96) adjusted for age, sex, BMI, smoking status, localization of OA, diabetes, maximum walking distance, total cholesterol, and cystatin C. Further adjustment for NT-proBNP, troponin I, and hs-C-reactive protein did not change the results appreciably (HR (95%CI) 1.56 (1.07-2.28); 1.75 (1.21-2.55); 2.32 (1.55-3.47) for Q2, Q3, and Q4 respectively, p for trend < 0.001). Conclusions: In subjects with OA, GDF-15 represents a potent predictor of decreased survival over >20 years, independently of conventional CV risk factors, renal, cardiac, and inflammatory biomarkers as well as walking disability, previously associated with increased mortality and lower extremity OA.
Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Alexander E Berezin

DOI: https://doi.org/10.1016/j.dsx.2015.09.016

Abstract:Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine, which belongs to super family of the transforming growth factor beta. GDF-15 is widely presented in the various cells (macrophages, vascular smooth muscle cells, adipocytes, cardiomyocytes, endothelial cells, fibroblasts), tissues (adipose tissue, vessels, tissues of central and peripheral nervous system) and organs (heart, brain, liver, placenta) and it plays an important role in the regulation of the inflammatory response, growth and cell differentiation. Elevated GDF-15 was found in patients with established CV diseases including hypertension, stable coronary artery disease, acute coronary syndrome, myocardial infarction, ischemic and none ischemic-induced cardiomyopathies, heart failure, atrial fibrillation, as well as stroke, type two diabetes mellitus (T2DM), chronic kidney disease, infection, liver cirrhosis, malignancy. Therefore, aging, smoking, and various environmental factors, i.e. chemical pollutants are other risk factors that might increase serum GDF-15 level. Although GDF-15 has been reported to be involved in energy homoeostasis and weight loss, to have anti-inflammatory properties, and to predict CV diseases and CV events in general or established CV disease population, there is no large of body of evidence regarding predictive role of elevated GDF-15 in T2DM subjects. The mini review is clarified the role of GDF-15 in T2DM subjects.
Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults

Miji Kim,Jeremy D Walston,Chang Won Won

DOI: https://doi.org/10.1093/gerona/glab201

2022-04-01

Abstract:Background: Growth differentiation factor 15 (GDF-15) is associated with disease progression, mitochondrial dysfunction, and mortality. Elevated GDF-15 level was recently reported to be associated with poorer physical performance in healthy adults. However, the association between serum GDF-15 level and sarcopenia in community-dwelling older adults has not been well characterized. Methods: We conducted cross-sectional (n = 929) and 2-year prospective analyses (n = 788) among participants aged 70-84 years enrolled in the Korean Frailty and Aging Cohort Study. Participants with an estimated glomerular filtration rate of <60 mL/min/1.73 m2 were excluded. Appendicular lean mass was measured using dual-energy x-ray absorptiometry. Sarcopenia status was determined according to the Asian Working Group for Sarcopenia-2019 algorithm. Results: At baseline, 16.6% of the participants had sarcopenia. Median GDF-15 concentration was higher in the sarcopenic group than in the non-sarcopenic group (1221 pg/mL vs 1019 pg/mL, p < .001). In the multivariate analysis adjusted for cardiometabolic risk and biological factors, the highest GDF-15 tertile (≥1245 pg/mL) had an increased likelihood of sarcopenia (odds ratio, 1.96; 95% confidence interval, 1.16-3.33) than the lowest tertile (<885 pg/mL). During the 2-year follow-up period, 67 (10.1%) individuals without sarcopenia at baseline developed sarcopenia. There were no significant associations between baseline serum GDF-15 levels and incident sarcopenia or its components (all p > .05). Conclusions: Elevated GDF-15 was associated with prevalent sarcopenia but not able to predict incident sarcopenia in the 2-year follow-up. Further studies are needed to explore the pathophysiological roles of GDF-15 in the development of sarcopenia.
Serum Growth Differentiation Factor-15/Albumin Ratio as a 2-Year Survival Marker of End-Stage Renal Disease Patients Initiating Maintenance Hemodialysis

Eu-Jin Lee,Haet-Bit Hwang,Soo-Hyun Han,Young-Rok Ham,Jin-Ah Shin,Kang-Wook Lee,Ki-Ryang Na,Dae-Eun Choi

DOI: https://doi.org/10.3390/diagnostics12020257

IF: 3.6

2022-01-20

Diagnostics

Abstract:It is important to identify risk factors related to mortality in end-stage renal disease (ESRD) patients starting renal replacement therapy. Recently, several studies proposed that growth-differentiation factor-15 (GDF-15) is a possible biomarker for the prognosis of patients on maintenance hemodialysis. Here, we investigated the predictive value of serum GDF-15/Albumin ratio on two-year mortality in ESRD patients initiating maintenance hemodialysis. The study was a single center, retrospective study on ESRD patients starting maintenance hemodialysis with a follow-up of two years. All patients completed laboratory test and bioimpedance spectroscopy prior to the initiation of the first dialysis. The patients were stratified into quartiles according to the quartiles of serum GDF-15/Albumin ratio. Among the 159 patients, the mean age was 61.78 ± 12.52 years and median survival was 20.03 ± 7.73 months. The highest GDF-15/Albumin quartile was significantly more associated with the increased risk of all-cause mortality than other quartiles (unadjusted hazard ratio (HR): 8.468, 95% CI 2.981–24.054, p < 0.001). Older age and a higher overhydration state were associated with GDF-15/Albumin ratio. The ROC analysis confirmed that the ability of the GDF-15/Albumin ratio to predict mortality was superior to GDF-15 or albumin alone. In conclusion, the GDF-15/Albumin ratio measured at the initial maintenance hemodialysis is an independent prognostic marker of two-year mortality in ESRD patients.

medicine, general & internal
Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Shangshi Zhang,Dongjun Dai,Xian Wang,Hongyan Zhu,Hongchuan Jin,Ruochi Zhao,Liting Jiang,Qi Lu,Fengying Yi,Xiangxiang Wan,Hanbin Cui

DOI: https://doi.org/10.1186/s12872-016-0250-2

IF: 2.174

2016-01-01

BMC Cardiovascular Disorders

Abstract:Background Recent studies have shown Growth differentiation factor–15 (GDF-15) that is a member of the transforming growth factor β (TGF-β) superfamily might be a potential predictive cytokine for the prognosis of Acute coronary syndrome (ACS). However, there are discrepancies in these studies. Methods Publication searches of the PubMed/Medline and EMBASE databases were performed without any time or ethnicity restrictions. The inclusion and exclusion criteria, when clear, were addressed. Random effects models were used for all analyses. Publication bias was tested using funnel plots and the Egger test. Results We identified eight eligible studies that provided mortality data. Five of these studies provided recurrent myocardial infarction (MI) data. The maximal duration of follow-up ranged from 6 months to 6 years. A significant association was found between the patients with the highest and lowest GDF-15 levels (overall analyses) in terms of mortality ( p < 0.00001; RR = 6.08; 95 % CI = 4.79–7.71) and recurrent MI ( p < 0.00001; RR = 1.76; 95 % CI = 1.49–2.07). We also found significant associations between the subgroup analyses stratified by ACS types, cutoff points and follow-up durations ( p < 0.001). The combined hazard ratio was high for GDF-15 to ACS (HR = 1.656, 95 % CI = 1.467–1.871). Conclusion High plasma GDF-15 levels are associated with an increased risk of mortality and recurrent MI in patients with ACS.
Growth Differentiation Factor-15 and Incident Chronic Kidney Disease: a Population-Based Cohort Study.

Lund University,Xu Biao,Borné Yan,Orho-Melander Marju,Melander Olle,Nilsson Jan,Christensson Anders,Engström Gunnar

DOI: https://doi.org/10.1186/s12882-021-02558-w

2021-01-01

BMC Nephrology

Abstract:Abstract Background The relationship between growth differentiation factor 15 (GDF-15) and the development of chronic kidney disease (CKD) is still unclear. We sought to examine whether plasma GDF-15 was related to incident CKD and kidney function decline using a large prospective cohort study. Methods 4318 participants of the Malmö Diet and Cancer Study-Cardiovascular Cohort were examined in 1991-1994. Incidence of CKD was followed prospectively by linkage with national patient registers. Estimated glomerular filtration rate (eGFR) was available for all participants at baseline, and was re-measured in a subgroup of 2744 subjects after 16.6 ± 1.49 years. Incidence of CKD was examined in relation to GDF-15 using Cox regression analysis. Logistic regression was used to examine the association of GDF-15 with eGFR change and eGFR-based CKD. Models were carefully corrected for potential confounders including baseline eGFR, N-terminal pro-B-type natriuretic peptide, and competing risk from death. Results 165 patients developed CKD after 19.2 ± 4.04 years of follow-up. The adjusted hazard ratio (95% confidence interval, CI) for CKD in 4th versus 1st quartile of GDF-15 was 2.37 (1.33, 4.24) (p for trend < 0.01). Each per 1 standard deviation increase in GDF-15 was associated with a decline in eGFR of − 0.97 mL/min/1.73 m2 (95% CI, − 1.49 ~ − 0.45; p < 0.001). GDF-15 was also significantly associated eGFR-based CKD in 2713 subjects with baseline eGFR ≥60 mL/min/1.73 m2. Conclusions GDF-15 predicted incidence of CKD and eGFR decline in the general population, independent of a wide range of potential risk factors and competing risk of death.
Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

Ali Javaheri,Mualla Ozcan,Lauren Moubarak,Karen E Smoyer,Michelle I Rossulek,James H Revkin,John D Groarke,Lisa C Tarasenko,Mikhail N Kosiborod

DOI: https://doi.org/10.1016/j.heliyon.2024.e35916

IF: 3.776

2024-08-08

Heliyon

Abstract:Growth differentiation factor-15 (GDF-15) is an emerging biomarker in several conditions. This SLR, conducted following PRISMA guidelines, examined the association between GDF-15 concentration and range of adverse outcomes in patients with heart failure (HF). Publications were identified from Embase® and Medline® bibliographic databases between January 1, 2014, and August 23, 2022 (congress abstracts: January 1, 2020, to August 23, 2022). Sixty-three publications met the eligibility criteria (55 manuscripts and 8 abstracts; 45 observational studies and 18 post hoc analyses of randomized controlled trials [RCTs]). Of the 19 outcomes identified, the most frequently reported longitudinal outcomes were mortality (n = 32 studies; all-cause [n = 27] or cardiovascular-related [n = 6]), composite outcomes (n = 28; most commonly mortality ± hospitalization/rehospitalization [n = 19]), and hospitalization/re-hospitalization (n = 11). The most common cross-sectional outcome was renal function (n = 22). Among longitudinal studies assessing independent relationships with outcomes using multivariate analyses (MVA), a significant increase in risk associated with higher baseline GDF-15 concentration was found in 22/24 (92 %) studies assessing all-cause mortality, 4/5 (80 %) assessing cardiovascular-related mortality, 13/19 (68 %) assessing composite outcomes, and 4/8 (50 %) assessing hospitalization/rehospitalization. All (7/7; 100 %) of the cross-sectional studies assessing the relationship with renal function by MVA, and 3/4 (75 %) assessing exercise capacity, found poorer outcomes associated with higher baseline GDF-15 concentrations. This SLR suggests GDF-15 is an independent predictor of mortality and other adverse but nonfatal outcomes in patients with HF. A better understanding of the prognostic role of GDF-15 in HF could improve clinical risk prediction models and potentially help optimize treatment regimens.
Improving quality of vascular access care for hemodialysis patients.

Ties M G van Andringa de Kempenaer,P. ten Have,J. Oskam

DOI: https://doi.org/10.1016/S1549-3741(03)29023-7

2003-04-01

The Joint Commission Journal on Quality and Safety

Abstract:
Elevated circulating growth differentiation factor 15 is related to decreased heart rate variability in chronic kidney disease patients

Lulu Wang,Jing Luo,Wenjin Liu,Xiaoqin Huang,Jie Xu,Yang Zhou,Lei Jiang,Junwei Yang

DOI: https://doi.org/10.1080/0886022x.2021.1880938

IF: 3.222

2021-01-01

Renal Failure

Abstract:BACKGROUND: Growth differentiation factor 15(GDF15) is a distant member of the superfamily of the transforming growth factor beta (TGF-β). It has been established that increased GDF15 levels are associated with an increased risk of cardiovascular disease. However, the detail effect of GDF15 on cardiovascular system in patients with chronic kidney disease (CKD) needs detail analysis.METHODS: Patients with CKD who did not need dialysis were enrolled in the study. Blood pressure (BP), endothelial function, pulse wave velocity (PWV) and heart rate variability (HRV) were taken in all subjects. Plasma GDF15 concentration was measured by an enzyme-linked immunosorbent assay.RESULTS: Among the 355 participants, the mean age was 57.4 (±14.2) years old and the mean estimated glomerular filtration rate (eGFR) was 50.1 (±33.2) mL/min/1.73m<sup>2</sup>. The average plasma GDF15 level was 1394.7 (±610.1) pg/mL. Higher GDF15 concentrations were significantly associated with decreased eGFR and increased urine protein-to-creatinine ratio (uPCR). In multivariable models, after adjusting for potential confounders, plasma GDF15 has negative concerning with HRV parameters including the standard deviation of the normal-to-normal (NN) interval (SDNN), the square root of the mean of the sum of the squares of differences between adjacent NN intervals (RMSSD) and Triangular Index.CONCLUSION: We observed there was a link between increased plasma of GDF15 and decreased HRV. The mechanisms and prediction of GDF15 in the cardiovascular disease with CKD needs further discussion and study.

urology & nephrology
A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure

Jin-Wen Luo,Wen-Hui Duan,Lei Song,Yan-Qiao Yu,Da-Zhuo Shi

DOI: https://doi.org/10.3389/fcvm.2021.630818

IF: 3.6

2021-11-05

Frontiers in Cardiovascular Medicine

Abstract:Background: Previous studies had reported increased circulating concentrations of growth differentiation factor-15 (GDF-15) in chronic heart failure (CHF), suggesting the potential prognostic significance of GDF-15 in this setting. To verify the relationship between the circulating GDF-15 levels and prognosis of CHF patients, we conducted an updated evidence-based meta-analysis. Methods: A comprehensive literature retrieval of PubMed, EMBASE, and Cochrane library was performed to collect the qualified studies that analyzed the prognostic value of GDF-15 in CHF from the inception of these online databases to September 25, 2021. The hazard ratio (HR) calculated for logGDF-15 of all-cause death and the related 95% confidence interval (CI) in multivariate analysis were used to measure the effect size. Additionally, subgroup analyses stratified by characteristics of the study participants were conducted for incremental evidence of GDF-15 in CHF with different clinical status. Results: A total of ten eligible studies involving 6,244 CHF patients were finally taken into the quantitative analysis. Results in the random-effects model indicated that there was an increased risk of 6% in all-cause mortality with a per 1LnU increase in baseline GDF-15 concentration (HR: 1.06, 95% CI: 1.03–1.10, P < 0.001). In stratified analyses, the association of GDF-15 with risk of all-cause mortality was found among chronic ischemic HF patients (HR:1.75, 95%CI: 1.24–2.48, P = 0.002), while the association was not found among chronic nonischemic HF patients (HR:1.01, 95%CI: 1.00–1.02, P = 0.219). Conclusion: The elevated GDF-15 is associated with an increased risk of all-cause mortality in CHF, especially, among CHF patients with ischemic etiology. The circulating GDF-15 might be a prognostic indicator in CHF patients. Registration Number: https://www.crd.york.ac.uk/PROSPERO ; CRD42020210796.

cardiac & cardiovascular systems
Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

Jianping Jiang,Yuanyuan Zhang,Jianghua Chen,Xiaobing Yang,Changlin Mei,Fei Xiong,Wei Shi,Wei Zhou,Xusheng Liu,Shiren Sun,Ping Zhang,Yixiang Zhang,Yanmin Zhang,Shuangxin Liu,Zhimin Zhang,Qizhan Lin,Yan Yu,Jianwei Tian,Weihong Luo,Xianhui Qin,Fan

DOI: https://doi.org/10.1159/000512385

2021-01-01

American Journal of Nephrology

Abstract:Background: The relation of tissue and circulating advanced glycation end products (AGEs) with mortality in hemodialysis (HD) patients remains inconclusive. We aimed to investigate the association of serum AGEs (CML) and tissue AGEs estimated by skin autofluorescence (SAF) with all-cause and cardiovascular disease (CVD) mortality, and examine the possible modifiers for the association in HD patients with by far the largest sample size in any similar studies. Methods: A total of 1,634 HD patients were included from the China Cooperative Study on Dialysis (CCSD), a multicenter prospective cohort study. The primary and secondary outcomes were all-cause mortality and CVD mortality, respectively. Results: The median follow-up duration was 5.2 years. Overall, there was a positive relation of baseline SAF levels with the risk of all-cause mortality (per 1 AU increment, adjusted hazard ratio (HR), 1.30; 95% confidence interval (CI): 1.12, 1.50) and CVD mortality (per 1 AU increment, adjusted HR, 1.36; 95% CI: 1.14, 1.62). Moreover, a stronger positive association between baseline SAF (per 1 AU increment) and all-cause mortality was found in participants with shorter dialysis vintage, or lower C-reactive protein levels (Both p interactions <0.05). Nevertheless, there was no significant association between serum CML and the risk of mortality. Conclusions: In patients undergoing long-term HD, baseline SAF, but not serum CML, was significantly associated with the risk of all-cause and CVD death.
The correlation between serum growth differentiation factor 15 and malnutrition in patients with end-stage kidney disease on hemodialysis

Lu Yao,Danshu Xie,Xiao Bi,Lilu Ling,W. Ding

DOI: https://doi.org/10.1080/0886022X.2023.2276911

IF: 3.222

2023-11-06

Renal Failure

Abstract:Abstract Objective Malnutrition commonly occurs in patients undergoing maintenance hemodialysis. Early detection of malnutrition could allow early interventions to prevent later complications. At present, there are not many biomarkers with high predictive value of end-stage kidney disease (ESKD)-related malnutrition, especially for early malnutrition in hemodialysis patients, which needs more in-depth research. Therefore, we performed a cross-sectional study on 97 patients to identify biomarkers for malnutrition in hemodialysis patients. Research Methods & Procedures 7-point subjective global assessment (SGA) was applied to evaluate the nutritional status of patients on hemodialysis. Serum levels of growth differentiation factor 15 (GDF15), albumin, pre-albumin, c-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), hemoglobin, low density lipoprotein-cholesterol, and high density lipoprotein-cholesterol were detected before hemodialysis. Logistic analysis and linear regression were used to analyze the association between GDF15 levels and the SGA score after adjustment for basic characteristics and laboratory findings. Results Among the 97 patients on hemodialysis, 51 had malnutrition (SGA < 6). There was no difference between the malnourished and well nourished (SGA ≥ 6) groups for dialysis duration, cholesterol, CRP, TNF-α, and hemoglobin. The malnutrition group had significantly lower grip strength (p < 0.05). GDF15 levels correlated negatively with the SGA score after adjustment for possible confounding factors [rho (male) = -0.312, rho(female)= -0.437;P(male) = 0.0181, P(female) = 0.005], and might contribute to the malnutritional status, the AUCs of GDF15 for malnutrition was 0.697 (p = 0.011) in male and 0.828 (p < 0.001) in female. Conclusions GDF15 is associated with malnutrition according to the SGA score in patients with ESKD on hemodialysis, suggesting that GDF15 might be involved in the pathogenesis of malnutrition patients with ESKD in this setting. Furthermore, GDF15 is likely to be a potential diagnostic biomarker for malnutrition according to the SGA score.

Medicine
Enzymatically driven transport: a kinetic theory for nuclear export.

Sanghyun Kim,M. Elbaum

DOI: https://doi.org/10.1016/j.bpj.2013.09.011

IF: 3.4

2013-11-05

Biophysical Journal

Abstract:
Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Dhayana Dallmeier,Hermann Brenner,Ute Mons,Wolfgang Rottbauer,Wolfgang Koenig,Dietrich Rothenbacher

DOI: https://doi.org/10.1373/clinchem.2016.254755

Abstract:Background: This study considered whether baseline concentrations and 12-month changes of growth differentiation factor 15 (GDF-15) are associated with subsequent cardiovascular events (CVEs) and total mortality in patients with stable coronary heart disease. Methods: Baseline GDF-15 serum concentrations were measured in 1073 participants in a cardiac rehabilitation program (median follow-up 10 years). GDF-15 associations with subsequent CVE and total mortality were evaluated by Cox-proportional hazards models adjusting for well-established cardiovascular risk factors (Model 2), plus N-terminal probrain natriuretic peptide, high-sensitivity (hs) CRP, and hs cardiac troponin T (Model 3). Results: In our study population [84.7% men, mean age 59 years, median baseline GDF-15 1232 ng/L (interquartile range, 916, 1674)] we observed 190 CVE and 162 deaths. Compared to participants with GDF-15 <1200 ng/L, increased risk for death was found in participants with GDF-15 ≥1200 and ≤1800 ng/L [hazard ratio (HR) 1.68 (95% CI, 1.08-2.62)] and with GDF-15 >1800 ng/L [HR 1.73 (1.02-2.94)], even in Model 3. The 12-month relative median change was -16.7%. As compared to participants with 12-month relative changes between -20% and 20%, GDF-15 increments >20% were associated with: a) an HR of 1.84 (1.04-3.26) for CVE in Model 2, but found nonsignificant in Model 3; (b) an HR of 2.26 (1.32-3.86) for death even in Model 3. Conclusions: GDF-15 at baseline is independently associated with subsequent CVE and 10-year total mortality. Twelve-month relative changes remained associated with subsequent CVE when adjusting for well-established cardiovascular risk factors, and with total mortality even after further adjustment for established cardiac biomarkers.
Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Ana Belen Mendez Fernandez,Andreu Ferrero-Gregori,Alvaro Garcia-Osuna,Sonia Mirabet-Perez,Maria Jose Pirla-Buxo,Juan Cinca-Cuscullola,Jordi Ordonez-Llanos,Eulàlia Roig Minguell

DOI: https://doi.org/10.1002/ehf2.12621

Abstract:Aims: The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth differentiation factor 15 (GDF-15) is superior to that of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with HFmrEF or HFpEF. Methods and results: Heart failure patients with either HFpEF or HFmrEF were included in the study. During their first visit to the HF unit, serum samples were obtained and stored for later assessment of GDF-15 and NT-proBNP concentrations. Patients were followed up by the HF unit. The main endpoint was all-cause mortality. A total of 311 patients, 90 (29%) HFmrEF and 221 (71%) HFpEF, were included. Mean age was 72 ± 13 years, and 136 (44%) were women. No differences were found in GDF-15 or NT-proBNP concentrations between both HF groups. During a median follow-up of 15 months (Q1-Q3: 9-30 months), 98 patients (32%) died, most (71%) of cardiovascular causes. Patients who died had higher median concentrations of GDF-15 (4085 vs. 2270 ng/L, P < 0.0001) and NT-proBNP (1984 vs. 1095 ng/L, P < 0.0001). A Cox multivariable model identified New York Heart Association Functional Class III (P = 0.04), systolic blood pressure (P = 0.01), left atrial diameter (P = 0.03), age >65 years (P < 0.0001), and GDF-15 concentrations (P = 0.01) but not NT-proBNP as independent predictors of all-cause mortality. The area under the curve was 0.797 for the basic model including NT-proBNP, and the area under the curve comparing the overall model was 0.819, P = 0.016 (DeLong's test). Integrated discrimination improvement index after the inclusion of GDF-15 in the model with the mortality risk factors was 0.033; that is, the ability to predict death increased by 3.3% (P = 0.004). Net reclassification improvement was 0.548 (P < 0.001); that is, the capacity to improve the classification of the event (mortality) was 54.8%. GDF-15 concentrations were divided in tertiles (<1625, 1625-4330, and >4330 ng/L), and survival curves were evaluated using the Kaplan-Meier technique. Patients in the highest tertile had the poorest 5 year survival, at 16%, whereas the lowest tertile had the best survival, of 78% (P < 0.001). Conclusions: Growth differentiation factor 15 was superior to NT-proBNP for assessing prognosis in patients with HFpEF and HFmrEF. GDF-15 emerges as a strong, independent biomarker for identifying HFmrEF and HFpEF patients with worse prognosis.
Prognostic Value of Growth Differentiation Factor-15 in Chinese Patients with Heart Failure: A Prospective Observational Study.

Hua Wang,Qingyong Chen,Yingying Li,Xianchao Jing,Jiefu Yang

DOI: https://doi.org/10.5603/cj.a2017.0068

IF: 3.487

2013-01-01

Cardiology Journal

Abstract:BACKGROUND Growth differentiation factor-15 (GDF-15), a biomarker associated with remodeling, oxidative stress and inflammation, has been used to stratify heart failure (HF) patients. However, its prognostic value in Chinese HF patients is still unknown. METHODS GDF-15 levels were examined on admission in 272 consecutive HF patients in Beijing Hospital (a Chinese tertiary medical center) by a commercial enzyme-linked immunosorbent assay. We recorded the incidence of all-cause mortality and/or readmission for HF during a median follow-up period of 558 days. Patients were stratified according to the tertiles of GDF-15. RESULTS Fifty-three (19.5%) patients died and 103 (37.9%) patients had major adverse cardiac events (MACE) which included the composite outcome of all-cause mortality or readmission for HF at the end of follow-up. Kaplan-Meier survival curves showed that the third tertile of GDF-15 was associated with increased rate of all-cause mortality (compared with the first and second tertiles, log rank p = 0.001 and 0.001, respectively) or MACE (compared with the first and second tertiles, log rank p = 0.002 and p < 0.001, respectively). In addition, multivariate Cox regression model showed that the highest tertile of GDF-15 was independently associated with increased risk of all-cause death (hazard ratio = 5.95, 95% confidence interval 1.88-18.78, p = 0.002) compared with the lowest tertile after adjustment for related clinical variables such as age, renal function or N-terminal pro-B-type natriuretic peptide. CONCLUSIONS Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with HF. It may potentially be used to stratify and prognosticate HF patients.
Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

Lyu Lyu,Cui Xv,Juan Xu,Zhenzhen Liu,Yanru He,Wenjing Zhu,Lin Lin,Qiang Yang,Yun Wei,Jinda Wang,Taoke Huang,Benchuan Hao,Hongbin Liu

DOI: https://doi.org/10.1007/s11239-024-03019-5

Abstract:The prognostic value of growth differentiation factor-15 (GDF-15) in predicting long-term adverse outcomes in coronary heart disease (CHD) patients remains limited. Our study examines the association between GDF-15 and adverse outcomes over an extended period in CHD patients and firstly assesses the incremental prognostic effect of incorporating GDF-15 into the Framingham risk score (FRS)-based model. This single-center prospective cohort study included 3,321 patients with CHD categorized into 2,479 acute coronary syndrome (ACS) (74.6%) and 842 non-ACS (25.4%) groups. The median age was 61.0 years (range: 53.0-70.0), and 917 (27.6%) were females. Mortality and major adverse cardiovascular events (MACEs) included cardiovascular mortality, myocardial infarction (MI), stroke, and heart failure (HF) (inclusive of HF episodes requiring outpatient treatment and/or hospital admission). Cox regression models assessed the associations between GDF-15 and the incidence of all-cause mortality and MACEs. Patients were stratified into three groups based on GDF-15 levels: the first tertile group (< 1,370 ng/L), the second tertile group (1,370-2,556 ng/L), and the third tertile group (> 2,556 ng/L). The C-index, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA) were used to assess incremental value. Over a median 9.4-year follow-up, 759 patients (22.9%) died, and 1,291 (38.9%) experienced MACEs. The multivariate Cox model indicated that GDF-15 was significantly associated with all-cause mortality (per ln unit increase, HR = 1.49, 95% CI: 1.36-1.64) and MACEs (per ln unit increase, HR = 1.29, 95% CI: 1.20-1.38). These associations persisted when GDF-15 was analyzed as an ordinal variable (p for trend < 0.05). Subgroup analysis of ACS and non-ACS for the components of MACEs separately showed a significant association between GDF-15 and both cardiovascular mortality and HF, but no association was observed between GDF-15 and MI /stroke in both ACS and non-ACS patients. The addition of GDF-15 to the FRS-based model enhanced the discrimination for both all-cause mortality (∆ C-index = 0.009, 95% CI: 0.005-0.014; IDI = 0.030, 95% CI: 0.015-0.047; continuous NRI = 0.631, 95% CI: 0.569-0.652) and MACEs (∆ C-index = 0.009, 95% CI: 0.006-0.012; IDI = 0.026, 95% CI: 0.009-0.042; continuous NRI = 0.593, 95% CI: 0.478-0.682). DCA suggested that incorporating GDF-15 into the FRS-based model demonstrated higher net benefits compared to FRS-based models alone (All-cause mortality: FRS-based model: area under the curve of DCA (AUDC) = 0.0903, FRS-based model + GDF-15: AUDC = 0.0908; MACEs: FRS-based model: AUDC = 0.1806, FRS-based model + GDF-15: AUDC = 0.1833). GDF-15 significantly associates with the long-term prognosis of all-cause mortality and MACEs in CHD patients and significantly improves the prognostic accuracy of the FRS-based model for both outcomes.
Growth Differentiation Factor 15 As a Composite Diabetic Cardiovascular Disease Indicator Including Heart Failure: A Systematic Review and Meta-Analysis

Suyi Xie,Qi Li,Erik Fung

DOI: https://doi.org/10.1016/j.cardfail.2020.09.055

IF: 6.592

2020-10-01

Journal of Cardiac Failure

Abstract:Introduction Recent studies suggested that growth differentiation factor 15 (GDF-15) may indicate heart failure and a constellation of cardiovascular co-morbidities in diabetic patients. Whereas N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is a cardiac-specific biomarker, GDF-15 is non-tissue-specific and may be a useful marker of global cardiovascular disease (CVD) burden, particularly in diabetes. In this systematic review and meta-analysis, we summarized the effects of elevated GDF-15 on the composite outcome of cardiovascular disease, events, and/or death in diabetic patients. Methods MEDLINE, EMBASE, CINAHL and Cochrane Library were queried for articles published from inception until February 2020. Longitudinal studies that reported data about the relationship between GDF-15 levels and CVD outcomes in diabetic patients were included. Pooled hazard ratios (HRs) for mortality were calculated and presented with 95% confidence intervals (CIs). Prespecified I2 threshold values of 25%, 50%, and 75% were used to indicate low, moderate, and high levels of heterogeneity, respectively. The risk of bias in the included studies was evaluated according to the criteria established by the Cochrane collaboration. Publication bias was assessed using funnel plot analysis. Results Seven studies with a total 15,805 diabetic patients were included (Fig. 1). The median follow-up ranged from 1.5 to 7.9 years. Pooled effect estimate suggested that elevated GDF-15 levels at baseline was associated with an increased risk for composite CVD-related outcome(s) (per standard deviation (SD) increase in log(GDF-15): HR 1.26, 95% CI 1.12-1.42, P = 0.0001, I2 for heterogeneity 85%, n = 15,651 patients) (Fig. 2a). When an unadjusted study was excluded, the pooled effect estimate remained statistically significant, with improvement in heterogeneity (per SD increase in log(GDF-15): HR 1.16, 95% CI 1.11-1.20, P <0.00001; I2 16%, n = 14,732 patients) (Fig. 2b). In four studies that reported an association between GDF-15 and all-cause mortality, the pooled analysis suggested that per SD increase in log(GDF-15) concentration, there was a significant increase in the risk for all-cause death (HR 1.76, 95% CI 1.23-2.53, P = 0.002); however, marked study heterogeneity (I2 92%, P <0.001) was observed (Fig. 2c). The pooled HR for all-cause death and GDF-15 remained significant even after excluding the unadjusted study. Conclusion Findings from this systematic review and meta-analysis suggest that elevated GDF-15 levels are associated with increased risk for incident cardiovascular endpoint(s) including acute cardiovascular events, heart failure and/or all-cause death in diabetic patients.

cardiac & cardiovascular systems
Growth Differentiation Factor-15 is a Biomarker for All-cause Mortality but Less Evident for Cardiovascular Outcomes: A Prospective Study

Xue Bao,Yan Borne,Biao Xu,Marju Orho-Melander,Jan Nilsson,Olle Melander,Gunnar Engstrom

DOI: https://doi.org/10.1016/j.ahj.2020.12.020

IF: 5.099

2021-01-01

American Heart Journal

Abstract:Background Previous studies have proposed growth differentiation factor-15 (GDF-15) as a predictor of adverse cardiovascular outcomes and mortality. The present study aimed to determine if such associations remain after accounting for death as a competing risk, and if GDF-15 provides superior prediction performance than other biomarkers. Methods Plasma GDF-15 levels and cardiovascular risk factors were measured in individuals without cardiovascular diseases (n = 4,143, aged 57.4 +/- 5.96 years, 38.6 % men) from Malmo Diet and Cancer-Cardiovascular Cohort and were followed up for more than 20 years. Incidence of coronary events, ischemic stroke, cardiovascular mortality, and all-cause mortality was studied in relation to GDF-15 using Cox proportional hazards regression, with adjustment for potential confounders. Confounding from death as competing risk was carefully checked using the Fine and Gray subdistribution hazard model. Predictive capabilities were further evaluated using C-statistics, continuous net reclassification improvement, and integrated discrimination improvement. Results During follow-up, 424 coronary events, 327 ischemic stroke, 368 cardiovascular deaths, and 1,308 all-cause deaths occurred. After controlling for death from other causes as competing events, only all-cause mortality remained sig-nificantly related to GDF-15. The addition of GDF-15 significantly improved prediction for all-cause mortality in addition to the traditional risk factors, high-sensitive C-reactive protein and N-terminal prohormone of brain natriuretic peptide. Only N-terminal prohormone of brain natriuretic peptide improved prediction for CVD mortality. Conclusions GDF-15 is a robust biomarker for all-cause mortality but less reliable for coronary event, ischemic stroke or cardiovascular mortality. Competing risk from death is an important consideration when interpreting the results.

On criticising Israel. Response from author of original paper. Comparison of the number of Palestinians killed by the Israeli Defence Force (IDF) with those killed in 9/11.

Monochromatic light sources in testing image intensifier tubes

Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults

Serum Growth Differentiation Factor-15/Albumin Ratio as a 2-Year Survival Marker of End-Stage Renal Disease Patients Initiating Maintenance Hemodialysis

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Growth Differentiation Factor-15 and Incident Chronic Kidney Disease: a Population-Based Cohort Study.

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

Improving quality of vascular access care for hemodialysis patients.

Elevated circulating growth differentiation factor 15 is related to decreased heart rate variability in chronic kidney disease patients

A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure

Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

The correlation between serum growth differentiation factor 15 and malnutrition in patients with end-stage kidney disease on hemodialysis

Enzymatically driven transport: a kinetic theory for nuclear export.

Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Prognostic Value of Growth Differentiation Factor-15 in Chinese Patients with Heart Failure: A Prospective Observational Study.

Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

Growth Differentiation Factor 15 As a Composite Diabetic Cardiovascular Disease Indicator Including Heart Failure: A Systematic Review and Meta-Analysis

Growth Differentiation Factor-15 is a Biomarker for All-cause Mortality but Less Evident for Cardiovascular Outcomes: A Prospective Study